{ "ok": true, "cik": "1626878", "ticker": "XBIT", "name": "XBiotech Inc.", "filings": [ { "form": "DEF 14A", "filed": "2026-10-02", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184326006362/0001171843-26-006362-index.htm" }, { "form": "10-Q", "filed": "2026-08-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184326005492/0001171843-26-005492-index.htm" }, { "form": "10-Q", "filed": "2026-05-14", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184326003419/0001171843-26-003419-index.htm" }, { "form": "10-K", "filed": "2026-03-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184326001561/0001171843-26-001561-index.htm" }, { "form": "8-K", "filed": "2025-12-09", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184325007836/0001171843-25-007836-index.htm" }, { "form": "10-Q", "filed": "2025-11-12", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184325007233/0001171843-25-007233-index.htm" } ], "events12m": 1, "healthWatch": { "window": "last 12 months", "since": "2025-10-05", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 1, "latest": { "filed": "2025-12-09", "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184325007836/0001171843-25-007836-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001626878.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1626878" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up XBiotech Inc. ($XBIT). Last filing: DEF 14A, 2026-10-02. 1 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2023-12-31", "revenue": 0, "revenueGrowth1y": -1, "revenueGrowthPerYear": null, "yearsOfData": 5, "operatingMargin": null, "operatingMarginPrior": -8.600997506234414, "netMargin": null, "operatingCashFlow": -18725000, "capitalSpending": 362000, "freeCashFlow": -19087000, "researchAndDevelopment": 32848000, "researchShareOfRevenue": null, "cash": 200023000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2019-12-31", "revenue": 0 }, { "fiscalYearEnd": "2020-12-31", "revenue": 43997000 }, { "fiscalYearEnd": "2021-12-31", "revenue": 18394000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 4010000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 0 } ], "totalEquity": 218846000, "totalAssets": 226615000, "equityRatio": 0.9657171855349381, "returnOnEquity": -0.11221132668634565, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "latestAudited": { "fiscalYearEnd": "2025-12-31", "revenue": null, "operatingCashFlow": -39920000, "cash": 125551000, "totalEquity": 140350000, "totalAssets": 150082000, "equityRatio": 0.9351554483548993 }, "revenueYearIsOld": true, "earningsPerShare": -0.81, "sharesOutstanding": 30438459, "bookValuePerShare": 7.189785790404173, "revenuePerShare": 0, "range80": { "low": 0, "high": 0, "baseline": 0, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 0, "high": 0 } }, "edgarette": "🔖 Exposure: revenue $0K (FY2023). Experience: revenue down 100.0% on the year; operating margin null, down from -860.1%. Soundness: equity 96.6% of assets, return on equity -11.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "XBiotech (XBIT) saw revenue fall 100% in FY2023 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 96.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
XBiotech Inc. against its own record and its peers
Revenue, on the yearPeer median 13.7%-100.0%Equity of assetsPeer median 40.3%96.6%Return on equityPeer median -1.1%-11.2%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "XBiotech (XBIT) saw revenue fall 100% in FY2023 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 96.6% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2023-12-31", "revenue": 0, "totalDebt": null, "cash": 200023000 }, "experience": { "revenueGrowth1y": -1, "revenueGrowthPerYear": null, "operatingMargin": null, "operatingMarginPrior": -8.600997506234414, "netMargin": null, "freeCashFlow": -19087000 }, "soundness": { "equityRatio": 0.9657171855349381, "returnOnEquity": -0.11221132668634565, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-10-05", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 1, "latest": { "filed": "2025-12-09", "url": "https://www.sec.gov/Archives/edgar/data/1626878/000117184325007836/0001171843-25-007836-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 0, "high": 0, "baseline": 0, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "credibility": null, "stress": null, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": null, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001626878.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1626878" }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$39.9M in FY2025)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -18725000, "investing": 61497000, "financing": -9000, "capitalSpending": 362000, "free": -19087000, "trend": [ { "fiscalYearEnd": "2019-12-31", "operating": -18270000, "free": -18474000 }, { "fiscalYearEnd": "2020-12-31", "operating": -65149000, "free": -68876000 }, { "fiscalYearEnd": "2021-12-31", "operating": 69445000, "free": 65920000 }, { "fiscalYearEnd": "2022-12-31", "operating": -14824000, "free": -15409000 }, { "fiscalYearEnd": "2023-12-31", "operating": -18725000, "free": -19087000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 200023000, "shortTerm": 0, "longTerm": null, "equityHoldings": null, "totalAssets": 226615000, "ladder": null, "currentRatio": 33.07, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$39.9M in FY2025)" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2023-12-31", "operating": -18725000, "investing": 61497000, "financing": -9000, "capitalSpending": 362000, "free": -19087000, "trend": [ { "fiscalYearEnd": "2019-12-31", "operating": -18270000, "free": -18474000 }, { "fiscalYearEnd": "2020-12-31", "operating": -65149000, "free": -68876000 }, { "fiscalYearEnd": "2021-12-31", "operating": 69445000, "free": 65920000 }, { "fiscalYearEnd": "2022-12-31", "operating": -14824000, "free": -15409000 }, { "fiscalYearEnd": "2023-12-31", "operating": -18725000, "free": -19087000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2023-12-31", "cash": 200023000, "shortTerm": 0, "longTerm": null, "equityHoldings": null, "totalAssets": 226615000, "ladder": null, "currentRatio": 33.07, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }